BMC Pediatrics | |
The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau | |
Research Article | |
A. Rodrigues1  C. L. Martins1  P. Aaby2  S. Biering-Sørensen2  S. M. Rasmussen2  A. Andersen2  M. Bjerregaard-Andersen3  S. Byberg4  C. S. Benn4  | |
[1] Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark;Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark;Department of Endocrinology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark;Bandim Health Project, Indepth Network, Apartado 861, 1004, Bissau Codex, Guinea-Bissau;Bandim Health Project, Research Center for Vitamins and Vaccines (CVIVA), Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark;OPEN, Odense Patient data Explorative Network, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; | |
关键词: Early measles vaccination; Growth; Non-specific effects; Sex-differential effects; Neonatal vitamin A supplementation; Season; | |
DOI : 10.1186/s12887-016-0738-z | |
received in 2016-07-26, accepted in 2016-11-26, 发布年份 2016 | |
来源: Springer | |
【 摘 要 】
BackgroundProviding an early, additional measles vaccine (MV) at 4.5 months of age has been shown to reduce child mortality in low-income countries. We studied the effects on growth at 9 and 24 months of age.MethodsA randomized controlled trial was conducted in Guinea-Bissau from 2003–2007 including 6,648 children. Children were randomized 1:1:1 to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B), or no vaccine at 4.5 months and Schwarz measles vaccine at 9 months (group C) Data on anthropometrics were obtained at enrolment at 4.5 months of age and again at 9 and 24 months of age. Analyses were stratified by sex, season of enrolment, and neonatal vitamin A supplementation (NVAS) status, as all these factors have been shown to modify the effect of early MV on mortality.ResultsOverall there was no effect of early MV on anthropometry at 9 months. At 24 months children who had received early MV had a significantly larger mid-upper-arm-circumference (MUAC/in cm) (Difference = 0.08; 95% CI (0.02;0.14)) compared with children in the control group; this effect was most pronounced among girls (0.12 (0.03;0.20)). The effect of early MV on MUAC remained significant in the dry season and in girls who received placebo rather than NVAS.ConclusionEarly MV was associated with a larger MUAC particularly in girls. These results indicate that a two-dose measles vaccination schedule might not only reduce child mortality but also improve growth.Trial registrationClinicalTrials.gov NCT00168558. Registered September 9, 2005, retrospectively registered
【 授权许可】
CC BY
© The Author(s). 2016
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311093724321ZK.pdf | 945KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]